Regeneron Pharmaceuticals has announced that two Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their primary endpoints.
Chris Lange Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) scored a win in a late-stage trial for the treatment of rheumatoid arthritis (RA). The company, in conjunction with Sanofi, announced that a Phase 3 monotherapy study…
Chris Lange Citigroup came out with a biotech upgrade of sorts on Thursday. The firm issued brand new Buy ratings on four of the largest names within the biotech space.
Regeneron Pharmaceuticals reported disappointing fourth-quarter financial results before the markets opened on Tuesday.
Chris Lange Regeneron Pharmaceuticals seems to have held up rather well against an analyst downgrade on Wednesday.
Jon C. Ogg Wednesday's top analyst calls include Apple, AT&T, DuPont, Fitbit, Huntington Bancshares, McDonald's, Merck, Newmont Mining and Sprint.
Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.
Friday’s top analyst upgrades, downgrades and initiations include AIG, Facebook, Gilead Sciences, Google, Regeneron Pharmaceuticals, Twitter, Valeant Pharmaceuticals and Vertex Pharmaceuticals.
Tuesday’s top analyst upgrades, downgrades and initiations include Amgen, Dow Chemical, Fitbit, Office Depot, SanDisk, Wells Fargo and Yum! Brands.
Monday was historic. But these types of movements are not one off. They usually come in clusters.
Merrill Lynch has looked at large cap biotech leaders and how interest rate increases may play a part in stock performance.
Wednesday's top analyst upgrades, downgrades and initiations include Apple, Cheniere Energy, First Solar, Hilton Worldwide, National Oilwell Varco and Disney.
Jon OggStocks were indicated higher on Tuesday morning after 5 days in a row of selling. Yet again we see the trend of investors finding a reason to buy every stock market…
ThinkstockRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) announced last Friday that the U.S. Food and Drug Administration (FDA) approved Praluent (alirocumab) Injection. Praluent is indicated as an adjunct to diet…
